Decentralised clinical trials, a potential solution for the complexity of rare disease clinical trials, but what impact may place have?

Since the commencement of our project, SPINs have increasingly taken the main stage in a variety of conferences in Canada.

From Big Pharma to Commons, insight into social innovation in rare disease from a French perspective, a book written by Gaëlle Krikorian

In our latest blog post, we look at the role of Health Technology Assessments in the distribution and allocation of health resources.